Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides , Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus , and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli , at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1. A method for treating autism in a subject in need thereof, said subject having autism and a gastrointestinal symptom, and said method comprising administering to said subject an amount of a pharmaceutical composition effective for treating a symptom of said autism, wherein said pharmaceutical composition comprises microflora of a disease screened fresh feces, wherein said microflora comprises viable non-pathogenic or attenuated Clostridium , and wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said administration of said pharmaceutical composition.
2. The method of claim 1 , wherein said pharmaceutical composition is administered orally.
3. The method of claim 1 , wherein said pharmaceutical composition is obtained from a disease screened fresh feces with the addition of a plurality of viable, non-pathogenic Clostridium spores.
4. A method for treating autism in a subject in need thereof, said subject having autism and a gastrointestinal symptom, and said method comprising administering to said subject an amount of a pharmaceutical composition effective for treating a symptom of said autism, wherein said pharmaceutical composition comprises a reconstituted feces comprising cultured viable non-pathogenic or attenuated microorganisms and resembling normal healthy human fecal flora, wherein said reconstituted feces comprises Clostridium , and wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said administration of said pharmaceutical composition.
5. The method of claim 4 , wherein said reconstituted feces is freeze-dried.
6. The method of claim 4 , wherein said pharmaceutical composition is administered orally.
7. The method of claim 4 , wherein said reconstituted feces comprises cultured viable non-pathogenic or attenuated microorganisms with the addition of a plurality of viable, non-pathogenic Clostridium spores.
8. A method for treating autism in a subject in need thereof, said subject having autism and a gastrointestinal symptom, and said method comprising administering to said subject an amount of a pharmaceutical composition effective for treating a symptom of said autism, wherein said pharmaceutical composition comprises a synthetic fecal composition of predetermined flora in proportional content that resembles a normal healthy human fecal flora, wherein said synthetic fecal composition comprises viable non-pathogenic or attenuated Clostridium , and wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said administration of said pharmaceutical composition.
9. The method of claim 8 , wherein said predetermined flora comprises no antibiotic resistant populations.
10. The method of claim 8 , wherein said pharmaceutical composition is administered orally.
11. The method of claim 8 , wherein said subject exhibits one or more symptom improvements selected from the group consisting of reduced repetitive action, sleeping through the night, increased eye contact, and progressively increased word power.
12. The method of claim 8 , wherein said pharmaceutical composition comprises no viable Bacteroides, Fusobacterium, Propionibacterium, Lactobacillus, Ruminococcus, Gemmiger, Desulfomonas, Peptostreptococcus, Bifidobacterium , or any combination thereof.
13. The method of claim 8 , wherein said synthetic fecal composition of predetermined flora is freeze-dried.
14. The method of claim 8 , wherein said method comprises administering to said subject an acid suppressant, an antacid, an H2 antagonist, a proton pump inhibitor or a combination thereof.
15. The method of claim 8 , wherein said pharmaceutical composition is formulated as an enteric coated capsule, an enteric coated microcapsule, a powder suitable for reconstitution, a naso-duodenal infusion, or for delivery in the form of an enema or a colonoscopic infusion.
16. The method of claim 8 , wherein said pharmaceutical composition is added to a food, a food additive, a dairy-based product, a soy-based product or a derivative thereof, a jelly, or a yogurt.
17. The method of claim 8 , wherein said subject is pretreated with an antibiotic, an acid suppressant, or both prior to administration of said pharmaceutical composition.
18. The method of claim 17 , wherein said antibiotic is selected from the group consisting of vancomycin, rifampicin, and nitroimidazole, chloramphenicol, and Septrin.
19. The method of claim 8 , wherein said pharmaceutical composition comprises between about 10 9 and about 10 11 viable, non-pathogenic bacteria.
20. The method of claim 8 , wherein said gastrointestinal symptom is selected from the group consisting of irritable bowel syndrome, chronic persistent diarrhoea, diarrhoea, flatulence, constipation, and alternating constipation/diarrhoea.